To further validate the therapeutic potential of DUSP4 inhibition in vivo, we administered the DUSP4 inhibitor BCI to Bmal1-/- mice with HDM-induced asthma in combination with DEX treatment (Fig 8A). Here, BMAL1 is linked to asthma.